Alpha Zero’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Alpha Zero’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-65	Closed	-$1.32K	–	109
2026 Q1	$1.32K	Buy	+65	New	+$13K	﹤0.01%	79

Other funds holding IRLA

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Alpha Zero's IRLA Position: Q2 2026 in Review

Alpha Zero sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026, closing a stake of 65 shares — an estimated $1.32K sold.

Alpha Zero first reported a position in IRLA in Q1 2026 and held it in 1 quarter. The position peaked at $1.32K in Q1 2026. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

Alpha Zero reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
Alpha Zero sold 65 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $1.32K.
Alpha Zero first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2026 and held it in 1 quarter.
Alpha Zero's IRulya Therapeutics Inc. Common Stock position peaked at $1.32K in Q1 2026.
26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Alpha Zero's 13F filing for Q2 2026, filed 20 Jul 2026.